GLP1R and myocardial infarction: Whilst some have reported the DPP-4 inhibitor, sitagliptin, and exendin-4 to have no effect on cardiomyocyte hypertrophy in experimental MI and type 1 diabetes, respectively, others have shown that GLP-1R activation with liraglutide reduces cardiomyocyte hypertrophy after both MI and high-fat feeding [15, 44–46].